Cerity Partners LLC Has $4.08 Million Stake in Hologic, Inc. (NASDAQ:HOLX)

Cerity Partners LLC reduced its stake in Hologic, Inc. (NASDAQ:HOLX) by 5.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 56,564 shares of the medical equipment provider’s stock after selling 3,320 shares during the quarter. Cerity Partners LLC’s holdings in Hologic were worth $4,078,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the stock. General Partner Inc. acquired a new stake in shares of Hologic in the fourth quarter worth $26,000. Venturi Wealth Management LLC lifted its position in Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after acquiring an additional 261 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock valued at $42,000 after acquiring an additional 260 shares during the period. Smartleaf Asset Management LLC grew its position in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 159 shares during the last quarter. Finally, Smithfield Trust Co increased its stake in shares of Hologic by 160.0% in the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 400 shares during the period. Institutional investors own 94.73% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on HOLX shares. Argus downgraded Hologic from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Royal Bank of Canada lowered their price objective on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research note on Thursday, February 6th. William Blair reaffirmed an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Stephens reissued an “overweight” rating and issued a $84.00 price target on shares of Hologic in a report on Thursday, February 6th. Finally, Raymond James restated an “outperform” rating and set a $90.00 price objective (down previously from $95.00) on shares of Hologic in a report on Thursday, February 6th. Eleven research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $84.62.

Hologic Price Performance

Shares of HOLX stock opened at $57.85 on Monday. The stock’s fifty day simple moving average is $62.47 and its 200 day simple moving average is $71.49. Hologic, Inc. has a one year low of $56.27 and a one year high of $84.67. The firm has a market cap of $12.98 billion, a price-to-earnings ratio of 18.25, a P/E/G ratio of 2.14 and a beta of 0.82. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.